m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02551)
Name
AMG 232
Synonyms
KRT-232
    Click to Show/Hide
Status
Phase 2
Structure
Formula
C28H35Cl2NO5S
InChI
1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1
InChIKey
DRLCSJFKKILATL-YWCVFVGNSA-N
PubChem CID
58573469
TTD Drug ID
D0C1WR
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ubiquitin-protein ligase E3 Mdm2 (MDM2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for AMG 232. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of AMG 232 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for AMG 232. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 232 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [1], [2]
References
Ref 1 The m(6)A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022 Jan 4;13(3):1019-1030. doi: 10.7150/jca.60381. eCollection 2022.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)